TRACING THE VIRUS

AESKU.GROUP offers now six new quantitative AESKULISA SARS-CoV-2 tests. Fast, reliable and easy to automate.Read more

AESKULISA SARS-CoV-2 IgM

Serves for determination of a first specific reaction of the immune system. Our tests are quantitative immunoassays for the demonstration of human IgM antibodies in serum or plasma.Read more

AESKULISA SARS-CoV-2 IgA

Assists in the detection of acute infections. Our tests are quantitative immunoassays for the demonstration of human IgA antibodies in serum or plasma.Read more

AESKULISA SARS-CoV-2 IgG

Serves for confirmation of pathogen contact and supports in immune status determination. Our tests are quantitative immunoassays for the demonstration of human IgG antibodies in serum or plasma.Read more

MEET US AT

Due to the actual situation, we are currently refraining from participating in trade fairs!Find out more about….

(Wendelsheim, Germany / Oakland, California,) AESKU.GROUP received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for AESKUSLIDES nDNA (Crithidia luciliae) with the new HELIOS AUTOMATED IFA SYSTEM. The kit is the second FDA cleared immunofluorescence assay on the HELIOS, after ANA HEp-2 (cleared in 2016), and will be followed by ANCA and tissue section slides. Read more...

“Laboratories have continued to return to IFA testing ever since the 2009 ACR position statement, which asserts that IFA is the Gold Standard for systemic autoimmune disease screening. The HELIOS improves traceability and turnaround time and eliminates the subjectivity and laborintensiveness of immunofluorescence assays, so labs can follow the ACR recommendations and ultimately improve the quality of patient testing." said Dr. Matthias, founder and CEO of the AESKU.GROUP.

“Laboratories performing IFA will be able to screen for ANA’s and then reflex to a very specific assay to detect anti-dsDNA antibodies using the most automated system on the market: the HELIOS. This a great tool to help clinicians diagnose Lupus patients. We look forward to making this kit available on the HELIOS to US clinical laboratories with the help of Grifols, our exclusive distribution partner in the US.” said Bruno Larida, Vice-President AESKU. INC.

The HELIOS is a revolutionary platform that both processes and analyzes patient immunofluorescence (IFA) samples in a single run. It is the first and only clinical platform to offer this level of IFA automation, overcoming the previous limitations of IFA testing and letting users return to the gold-standard method for Autoimmunity screening. Over 300 HELIOS systems are in clinical use worldwide, in over 40 countries.

Kimberly Pacella, Director of Clinical Operations at HNL in Allentown, PA chose the HELIOS to address a surge in IFA orders: “In order to absorb all that volume without adding staffing, we need to be able to do things more efficiently. This [HELIOS] will absolutely help with that.” said Pacella.

The HELIOS system and its FDA cleared kits will be displayed at the American Association of Clinical Chemistry meeting and is available in the U.S.

"Our pathology network, SDS Laboratories, has 9 Helios platforms installed in various laboratories throughout Australia. The level of scientific and technical support offered with the systems has been exemplary and unparalleled in my years of experience in diagnostic pathology.”

“On this basis, I have no hesitation in offering my avid recommendation of the products and support of Aesku.”